Model List of Essential Medicines

McLean-Tooke APC, Bethime CA, Fay AC, Spickett GP Adrenahne in the treatment of anaphylaxis what is the evidence Br Med J 2003 327 1332-1335. WHO Model List of Essential Medicines, ed 15, March 2007, available from http //www.who.int/ medicines/publications/essentialmedicines/en (accessed December 17. 2008). 

Individual health professionals normally use fewer than 50 different medicines, the WHO Model List of Essential Medicines contains about 300 active substances... 

A major step towards rational use of medicines was taken in 1977, when WHO established the 1st Model List of Essential Medicines to assist countries in formulating their own national lists. In 1985, the present definition of rational use was agreed at an international conference in Kenya. In 1989, the International Network for the Rational Use of Drugs (INRUD) was formed to conduct multi-disciplinary intervention research projects to promote more rational use of medicines (e-mail inrud msh.org, web site http //www.msh.org/inrud). Following this. 

WHO. The selection and nse of essential medicines Report of the WHO Expert Committee (including the 15th WHO model list of essential medicines). Geneva World Health Organization 2007. (Technical report series no 946). 

Included in the WHO 14th Model List of Essential Medicines (2006), lopinavir only in the combination with low dose ritonavir. 

WHO. The 15th WHO model list of essential Medicines. 2007 March. Available from URL http //www.who.int/medicines/publications/ EMLlTpdf... 

This TTA is an injectable core medicine listed in the World Health Organization s (WHO) Model list of essential medicines [41], Atropine (Fig. 1) acts as a competitive MR antagonists used clinically as, e.g. parasympatholytic for pre-anaesthesia medication, ophthalmologic procedures and as antidote for the therapy of anticholinesterase poisoning [42,43], A corresponding PK study in man monitoring atropine as antidote by LC-MS/MS is referred in this chapter [44],... 

Artemether (N2) and arteether (N3) are the most well-studied analogs among many synthetic derivatives and are used in malaria-prone regions, particularly India (131). Artemether and sodium artesunate (a hemisuccinate derivative of dihydroartemisinin) (N4) have been added by the World Health Organization to its Model List of Essential Medicines (132). 

Lindenberg, M., Kopp, S. and Dressman, J.B. (2004) Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. European Journal of Pharmaceutical Sciences, 58 (2), 265. 

WHO (2006) Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms. Technical Report Series, No. 937,... 

He presented the Committee with information on the new structure of the Department as a result of changes in December 2004 and January 2005. Activities and operations were in line with the four-year Medicines Strategy, development and promotion of standards, international treaties, the WHO Model List of Essential Medicines and the WHO Model Formulary, collection of evidence for medicines policies (including national medicines policies, access to and rational use of medicines and adherence to treatment), and promotion of consistency in pharmaceutical matters in United Nations agencies in a collaborative framework. 

The Committee noted some of the activities of the United Nations Children s Fund (UNICEF) related to pharmaceuticals. These include qualification of suppliers, specifications for products, contracts with suppliers and the management of warehouses. It was noted that UNICEF uses the WHO lists of prequalified products and manufacturers in the procurement of HIV/ AIDS products and vaccines. Due to the lack of prequalified antimalarial products, an interim assessment process was used. Another problem identified was that some products included in the WHO Model List of Essential Medicines were not available on the market. 

Subsequent to the recommendations made at the previous meeting of the Committee, the Secretariat took steps towards the revision of the published list of comparator products (published in WHO Technical Report Series, No. 902, Annex 11). The Committee noted that the updates received from the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) had been included by the Secretariat and that the list was also compared with the WHO Model List of Essential Medicines. The list of comparator products had been circulated and comments were awaited by 30 November 2005. The Committee adopted the list, subject to any minor changes based on comments received, and recommended that ... 

The revised document was presented to the Committee. It was noted that the tables should be regularly updated to reflect the status of the WHO Model List of Essential Medicines. Minor corrections were recommended and incorporated. The Committee adopted the document (Annex 8). 

Those pharmaceutical products that satisfy the health care needs of the majority of the population. WHO s Expert Committee on the Selection and Use of Essential Medicines updates the WHO Model List of Essential Medicines at two-year intervals. Each country may use this model to generate its own list of essential pharmaceutical products. 

Procurement agencies may find that many of the products they require are on WHO s Model List of Essential Medicines, which contains medicines of proven safety and efficacy and is updated periodically 4. Procurement agencies should focus on procurement of medicines reflected in the Model List. They will find this list a useful reference for establishing specifications for the medicines needed for their purposes. 

Furthermore, the dose that is to be used for the calculation is the highest dose indicated in the Model List of Essential Medicines (EML). In... 

The substances listed in the 14th WHO Model List of Essential Medicines (EML) of March 2005 have been evaluated and classified according to the revised criteria given above. 

Compounds introduced to the WHO Model List of Essential Medicines since March 2005 for which no certain classification had been previously reported (these compounds also appear in Table 1 and Table 2)... 

Report of the WHO Expert Committee (including the 13th Model List of Essential Medicines). WHO Technical Report Series, No. 920, 2004 (133 pages)... 

---